Novartis AG vs Warner Music Group Corp — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Warner Music Group Corp trades at $28.87 (market cap $15.12B). The key difference: Novartis AG is far larger — about 17.8× Warner Music Group Corp's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Warner Music Group Corp for 96 Days on average.
| NVS | WMG | |
|---|---|---|
Market Cap | $268.57B | $15.12B |
Volume | 1,532,573 | 2,966,414 |
Sector | Health | Media |
52-Week High | $168.62 | $34.72 |
52-Week Low | $121.80 | $23.65 |
Typical Hold Time | 82 Days | 96 Days |
Enterprise Value | $309.89B | $19.42B |
Dividend Yield | 3.31% | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
WMG trades at $28.16, up 1.99% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company is expanding margins through streaming growth and AI partnerships. Cash flow is projected to improve significantly in 2026, supporting future dividends and investments.
The outlook is positive, with a consensus price target of $39.50 implying substantial upside. Key opportunities include AI-driven content curation and market share gains, while risks involve execution on tech transitions and potential copyright disputes. The stock presents a compelling growth story if operational momentum continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →